Squamous Cell Carcinoma of the Head and Neck – Geographic Focus: China – China In-Depth – Squamous Cell Carcinoma of the Head and Neck

China’s SCCHN market is undergoing rapid transformation, driven by the expanding use of systemic therapies beyond traditional surgery and radiotherapy. Current treatment options include chemotherapy, EGFR inhibitors such as Erbitux (cetuximab), Taixinsheng (nimotuzumab), and Meiyouheng (becotatug vedotin), as well as increasing uptake of immune checkpoint inhibitors. Key immunotherapies include Keytruda (pembrolizumab), Opdivo (nivolumab), Tuoyi (toripalimab), AiRuiKa (camrelizumab), Baizean (tislelizumab), Aniko (penpulimab), Ketailai (tagitanlimab), and Anyouping (finotonlimab). A robust late-phase pipeline—featuring Izabren (Sichuan Biokin), dostarlimab (GSK), QL1706 (Qilu Pharmaceutical), and volrustomig (AstraZeneca)—is expected to reshape competitive dynamics, clinical decisionmaking, and pricing strategies over the next 10 years. This report examines China’s evolving SCCHN treatment landscape and evaluates how key clinical and nonclinical factors—including price dynamics, NRDL inclusion, and anticipated generic or biosimilar competition—are likely to influence launch potential and therapy uptake across the forecast period.

Questions answered

• What is the diagnosed incidence of SCCHN in China, and how are these patients treated today?
• What are the interviewed experts’ insights into current therapies and their views on emerging treatments?
• What are the key market access considerations, and how are they likely to impact the uptake of emerging therapies in this market?
• What are the key drivers and constraints in China, and how will the market evolve over the forecast period?

Product description

China In-Depth offers comprehensive market intelligence with world-class epidemiology, insight into the China-specific market access landscape, current and emerging therapies, and drug forecasts supported by detailed primary and secondary research, enabling you to:

• Optimize your long-term disease and development strategy in China.
• Quantify market potential for your pipeline assets and those of your competitors.
• Understand current treatment paradigms, the complex access and reimbursement environment, and the current and future therapeutic landscape.
• Gauge the commercial outlook and impact of key market events.